信迪利单抗联合仑伐替尼治疗中晚期肝癌临床观察  

Clinical observation on sindilizumab combined with lenvastinib in the treatment of advanced liver cancer

作　　者：王勇军[1] 王志英 王红英[3] 李林[4] WANG Yongjun;WANG Zhiying;WANG Hongying;LI Lin(Department of Oncology,Nanfeng County People’s Hospital,Nanfeng 344500,China;Nanfeng County Center for Disease Control and Prevention,Nanfeng 344500,China;Department of Pharmacy,Nanfeng County Hospital of Traditional Chinese Medicine,Nanfeng 344500,China;Department of Thoracic Oncology,Jiangxi Cancer Hospital,Nanchang 330013,China)

机构地区：[1]南丰县人民医院肿瘤内科,江西南丰344500 [2]南丰县疾病预防控制中心,江西南丰344500 [3]南丰县中医院药剂科,江西南丰344500 [4]江西省肿瘤医院胸部肿瘤内科,江西南昌330013

出　　处：《肿瘤基础与临床》2024年第5期514-517,共4页journal of basic and clinical oncology

基　　金：江西省卫生健康委科技计划项目(20192170、skjp220202972)。

摘　　要：目的探讨信迪利单抗联合仑伐替尼治疗中晚期肝癌的临床效果。方法选取2019年1月到2023年1月南丰县人民医院收治的42例中晚期肝癌患者作为研究对象,按照进院诊疗时间分为2组,每组21例。对照组口服仑伐替尼,观察组口服仑伐替尼联合静脉滴注信迪利单抗,比较2组患者的近期疗效、生存期、肝功能指标、肿瘤标志物、不良反应。结果观察组疾病控制率85.7%,高于对照组的57.1%(χ^(2)=4.200,P=0.040)。观察组OS、PFS均长于对照组增长(t=12.654,P<0.001;t=14.324,P<0.001)。观察组治疗后血清谷草转氨酶、总胆红素、谷丙转氨酶水平均低于对照组(t=5.645,P<0.001;t=7.012,P<0.001;t=6.654,P<0.001)。观察组治疗后血清CA199、CEA、AFP水平均低于对照组(t=7.689,P<0.001;t=7.342,P<0.001;t=15.698,P<0.001)。2组不良反应总发生率比较差异无统计学意义(χ^(2)=2.043,P=0.153)。结论信迪利单抗联合仑伐替尼治疗中晚期肝癌效果良好,安全性较高,为无法进行手术的中晚期肝癌患者治疗提供了新的选择。Objective To investigate the clinical effect of sindilizumab combined with lenvatinib in the treatment of advanced liver cancer.Methods The 42 patients with advanced liver cancer in the Nanfeng County People’s Hospital from January 2019 to January 2023 were selected as the study objects and divided into two groups according to the time of admission and treatment.The 21 patients in the control group was given with oral renvastinib,and 21 patients in the observation group was given with oral renvastinib and intravenous sinillizumab.The short-term efficacy,survival,liver function indexes,tumor markers and adverse reactions of the two groups were compared.Results The disease control rate in the observation group was 85.7%,which was higher than that in the control group(57.1%)(χ^(2)=4.200,P=0.040).The overall survival and progression-free survival in the observation group were longer than those in the control group(t=12.654,P<0.001;t=14.324,P<0.001).After treatment,the levels of serum aspartate transaminase,total bilirubin,alanine aminotransferase in the observation group were lower than those in the control group(t=5.645,P<0.001;t=7.012,P<0.001;t=6.654,P<0.001).After treatment,the levels of serum carbohydrate antigen 199,carcinoembryonic antigen,alpha fetoprotein in the observation group were lower than those in the control group(t=7.689,P<0.001;t=7.342,P<0.001;t=15.698,P<0.001).There was no significant difference in the total incidence of adverse reactions between the two groups(χ^(2)=2.043,P=0.153).Conclusion Sindilizumab combined with lenvatinib in the treatment of advanced liver cancer has good clinical effect and high safety,providing a new treatment method for patients who cannot be operated in the advanced stage.

关 键 词：信迪利单抗 仑伐替尼 中晚期肝癌 

分 类 号：R735.7[医药卫生—肿瘤]